Research Output per year
Research Output per year
Personal profile
Training Experience
| 2006 | Residency, Children's Hospital of Philadelphia |
| 2009 | Fellowship, Children's Hospital of Philadelphia |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MD, Medicine, Tulane University
… → 2003
MPH, Public Health, Tulane University
… → 1999
Fingerprint
Dive into the research topics where Angela J Waanders is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Baseline ophthalmic findings and complications in pediatric patients treated with MEK inhibitors
Hazariwala, V., Rossen, J. L., Lasky-Zeid, J., Waanders, A. & Bohnsack, B. L., Apr 2025, In: Journal of AAPOS. 29, 2, 104157.Research output: Contribution to journal › Article › peer-review
Open Access -
Novel SMARCA4 Variant in an Infant with Atypical Teratoid Rhabdoid Tumor
Haldipurkar, S. K., Damodharan, S. N., Rathbun, P., Yap, K. L., Wadhwani, N. & Waanders, A. J., Apr 1 2025, In: Journal of pediatric hematology/oncology. 47, 3, p. 148-152 5 p.Research output: Contribution to journal › Article › peer-review
-
Socioeconomic Factors Associated With Participation in Postmortem Tissue Donation in Pediatric Central Nervous System Tumors
Kabat, J. M., Boland, L. K., Williams, M., Michelson, I., Lenzen, A., Plant-Fox, A. S., Wadhwani, N. & Waanders, A. J., Feb 2025, In: Pediatric Blood and Cancer. 72, 2, e31417.Research output: Contribution to journal › Article › peer-review
Open Access -
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02668-y)
Kilburn, L. B., Khuong-Quang, D. A., Hansford, J. R., Landi, D., van der Lugt, J., Leary, S. E. S., Driever, P. H., Bailey, S., Perreault, S., McCowage, G., Waanders, A. J., Ziegler, D. S., Witt, O., Baxter, P. A., Kang, H. J., Hassall, T. E., Han, J. W., Hargrave, D., Franson, A. T. & Yalon Oren, M. & 22 others, , May 2024, In: Nature Medicine. 30, 5, p. 1500 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access1 Scopus citations -
Editor's Note: BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas
Olow, A., Mueller, S., Yang, X., Hashizume, R., Meyerowitz, J., Weiss, W., Resnick, A. C., Waanders, A. J., Stalpers, L. J. A., Berger, M. S., Gupta, N., James, C. D., Petritsch, C. K. & Haas-Kogan, D. A., Dec 1 2024, In: Clinical Cancer Research. 30, 23, p. 5494 1 p.Research output: Contribution to journal › Editorial › peer-review